VANGUARD GROUP INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$297,347,619
+47.9%
11,275,981
-3.5%
0.01%
+40.0%
Q2 2023$200,981,949
+0.5%
11,684,997
-3.1%
0.01%0.0%
Q1 2023$200,008,785
+147.8%
12,063,256
+13.9%
0.01%
+150.0%
Q4 2022$80,706,888
-18.8%
10,591,455
+5.9%
0.00%
-33.3%
Q3 2022$99,442,000
+10.7%
10,004,271
+1.1%
0.00%0.0%
Q2 2022$89,851,000
-6.1%
9,895,537
+5.0%
0.00%
+50.0%
Q1 2022$95,655,000
-38.5%
9,424,112
+1.0%
0.00%
-50.0%
Q4 2021$155,653,000
-64.8%
9,331,683
-1.1%
0.00%
-63.6%
Q3 2021$442,238,000
-36.0%
9,435,412
-16.7%
0.01%
-35.3%
Q2 2021$690,623,000
+20.0%
11,329,129
+21.3%
0.02%
+6.2%
Q1 2021$575,417,000
+25.6%
9,341,186
+45.0%
0.02%
+23.1%
Q4 2020$458,042,000
+93.9%
6,441,312
+2.3%
0.01%
+62.5%
Q3 2020$236,193,000
+25.2%
6,295,118
+8.8%
0.01%
+14.3%
Q2 2020$188,698,000
+174.6%
5,786,518
+144.2%
0.01%
+133.3%
Q1 2020$68,705,000
-8.4%
2,369,131
+10.7%
0.00%0.0%
Q4 2019$75,042,000
+119.4%
2,140,996
+34.4%
0.00%
+200.0%
Q3 2019$34,201,000
+1352.9%
1,592,950
+1725.1%
0.00%
Q2 2019$2,354,00087,2820.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders